human
viral
challeng
hvc
model
mani
decad
help
understand
respiratori
virus
role
diseas
pathogenesi
control
set
use
small
number
volunt
remov
commun
exposur
infect
experiment
model
enabl
proof
concept
work
undertaken
novel
therapeut
includ
vaccin
immunomodul
antivir
well
new
diagnost
crucial
unlik
convent
phase
studi
challeng
studi
includ
evalu
efficaci
endpoint
guid
decis
optimis
subsequ
field
studi
recommend
fda
thu
licens
studi
follow
strategi
optimis
benefit
studi
identifi
possibl
threat
earli
minimis
risk
subsequ
volunt
also
maximis
benefit
scarc
resourc
avail
research
group
invest
research
inspir
principl
replac
reduct
refin
commonli
appli
preclin
phase
hvc
studi
allow
refin
reduct
subsequ
develop
phase
acceler
progress
toward
statist
power
phase
studi
breadth
data
gener
challeng
studi
allow
explor
wide
rang
variabl
endpoint
taken
pivot
phase
studi
describ
diseas
burden
acut
respiratori
viral
infect
current
convent
develop
strategi
fail
produc
therapeut
meet
clinic
need
author
describ
hvc
model
util
increas
scientif
understand
progress
promis
therapeut
develop
contribut
model
elucid
virushost
interact
regard
viral
pathogen
bodi
immunolog
respons
discuss
along
util
assist
develop
novel
diagnost
futur
applic
model
also
explor
review
aim
describ
human
viral
challeng
model
histori
util
specif
recent
use
potenti
acceler
develop
novel
therapi
unmet
medic
need
respiratori
diseas
acut
respiratori
infect
ari
manifest
upper
uri
lower
lri
respiratori
tract
infect
may
move
two
compart
ari
repres
common
infecti
diseas
predominantli
viral
aetiolog
global
burden
ari
substanti
signific
morbid
mortal
occur
children
elderli
immunocompromis
uk
alon
period
respiratori
diseas
caus
estim
excess
winter
death
usa
influenza
respiratori
syncyti
viru
rsv
caus
substanti
mortal
especi
among
peopl
age
older
howev
although
death
industrialis
world
wide
report
develop
countri
feel
burden
particularli
estim
million
child
death
ari
death
occur
africa
southeast
asia
millennium
summit
unit
nation
led
set
millennium
develop
goal
studi
report
progress
made
meet
goal
develop
countri
conclud
preval
ari
health
expenditur
per
capita
gross
domest
product
directli
associ
preval
diseas
viral
heterogen
associ
ari
well
establish
past
human
rhinoviru
hrv
identifi
viru
frequent
associ
respiratori
ill
infect
annual
averag
upper
respiratori
infect
autumn
outbreak
hrv
coronavirus
cov
influenza
respiratori
syncyti
viru
rsv
parainfluenza
virus
piv
next
frequent
recent
evalu
ill
children
ten
year
age
australia
south
east
asia
latin
america
emphasis
viral
heterogen
impact
ari
children
experienc
individu
influenzalik
ill
ili
episod
rhinovirusenteroviru
preval
influenza
follow
adenoviru
adv
piv
rsv
cov
human
metapneumoviru
hmpv
human
bocaviru
hbov
percentag
children
miss
school
childcar
hbov
influenza
compar
data
two
report
one
found
report
despit
separ
year
similar
singl
except
hbov
discov
tabl
discuss
later
feng
et
al
describ
detail
distribut
ari
caus
hospitalis
age
group
observ
rsv
predominantli
observ
young
elderli
influenza
although
signific
young
notic
predomin
elderli
interestingli
observ
codetect
virus
tend
occur
commonli
younger
age
group
particularli
age
five
rhinoviru
common
cold
hrv
infect
often
consid
trivial
significantli
contribut
miss
day
work
school
though
infect
typic
selflimit
hrv
infect
throughout
year
mani
case
manifest
symptom
nasal
congest
rhinorrhoea
sneez
sore
throat
cough
hrv
known
primari
caus
ari
sever
contribut
factor
exacerb
atop
diseas
eg
asthma
well
condit
chronic
obstruct
pulmonari
diseas
copd
hrv
infect
associ
signific
econom
implic
well
import
contributor
sinus
otiti
media
bronchiti
primari
pneumonia
hrv
consider
caus
morbid
specif
atrisk
group
infant
elderli
immunocompromis
alreadi
mention
chronic
respiratori
diseas
asthma
copd
cystic
fibrosi
present
hrv
consid
number
one
caus
asthma
exacerb
asthma
complex
diseas
characteris
chronic
airway
inflamm
histori
respiratori
symptom
wheez
short
breath
chest
tight
cough
time
symptom
vari
intens
year
million
peopl
worldwid
affect
asthma
approxim
peopl
die
result
mani
death
due
suboptim
longterm
medic
care
delay
obtain
help
sever
exacerb
diseas
treatment
prevent
worsen
symptom
therapi
mild
moder
asthma
avert
relaps
ie
symptom
worsen
treatment
stop
signific
unmet
medic
need
human
challeng
model
use
investig
viral
pathogen
recent
public
asthma
challeng
model
focus
asthmat
host
respond
hrv
infect
work
ongo
suscept
viral
induc
asthma
worsen
innat
immun
dysregul
induct
innat
type
respons
nasal
bronchial
epitheli
secret
pathogenesi
rhinovir
infect
along
ari
exacerb
airway
diseas
investig
extens
impair
host
respons
viru
infect
better
understand
mechan
abnorm
immun
respons
potenti
develop
novel
therapeut
target
virusinduc
exacerb
use
hvc
model
despit
previou
research
work
multipl
small
molecul
antivir
pleconaril
test
use
experiment
challeng
model
field
studi
current
licens
treatment
hrv
infect
compound
test
hrv
vapendavir
prevent
releas
viral
rna
target
cell
demonstr
reduct
peak
viral
load
hvc
model
subsequ
studi
asthmat
complet
although
publish
compound
limit
effect
pirodavir
intranas
capsidbind
molecul
reach
phase
clinic
trial
hrv
prevent
treatment
although
compound
decreas
viral
replic
shed
fail
show
signific
reduct
durat
sever
symptom
proteas
inhibitor
rupintrivir
that
prevent
cleavag
viral
protein
requir
replic
test
hrv
challeng
trial
rupintrivir
well
toler
reduc
viral
load
respiratori
symptom
howev
studi
natur
infect
significantli
affect
viral
load
symptom
sever
treatment
zinccontain
product
wide
discredit
demonstr
withdraw
cochran
report
jama
editori
current
treatment
hrv
infect
primarili
consist
overthecount
otc
medicin
manag
symptom
also
licens
vaccin
progress
develop
multival
vaccin
develop
area
hamper
sheer
number
serotyp
need
cover
present
despit
hrv
associ
adult
asthma
exacerb
childhood
exacerb
hrvspecif
asthma
therapi
better
understand
interact
viru
host
new
therapi
monoclon
antibodi
antiig
omalizumab
mepolizumab
along
small
molecul
care
target
specif
immun
signal
pathway
hrvspecif
prophylact
treatment
may
becom
practic
order
prevent
exacerb
design
new
therapeut
could
potenti
improv
efficaci
directli
act
inhibit
viral
replic
allevi
symptom
asthma
copd
influenza
viru
wellknown
human
pathogen
caus
sever
morbid
mortal
particularli
older
patient
comorbid
immunocompromis
first
pandem
viru
st
centuri
hospitalis
us
alon
result
death
world
health
organ
global
pool
analysi
laboratoryconfirm
hospitalis
pandem
patient
countri
reveal
patient
admit
intens
care
unit
die
morbid
obes
might
risk
factor
hospitalis
andor
death
obes
confirm
factor
associ
higher
likelihood
admiss
hospit
influenzainfect
patient
pandem
consid
mild
howev
classic
w
shape
age
distribut
curv
infect
pandem
viru
observ
high
mortal
young
old
addit
spike
death
amongst
young
healthi
pandem
previou
outbreak
occur
success
wave
despit
nation
polici
favour
use
antivir
drug
patient
receiv
admiss
hospit
mani
given
antibiot
lack
real
perceiv
real
world
efficaci
current
avail
antivir
lead
overus
antibiot
subsequ
problem
may
aris
yearli
season
morbid
mortal
influenza
result
hospitalis
death
mainli
among
highrisk
group
year
epidem
season
influenza
estim
result
million
case
sever
ill
death
worldwid
first
world
industrialis
countri
death
associ
influenza
occur
among
peopl
age
older
clinic
hospit
mani
countri
overwhelm
peak
ill
period
substanti
econom
cost
viru
well
characteris
two
surfac
protein
haemagglutinin
ha
neuraminidas
na
import
vaccin
antivir
develop
effect
season
influenza
epidem
develop
countri
fulli
known
research
estim
death
children
five
year
age
influenzarel
lower
respiratori
tract
infect
found
develop
countri
current
vaccin
antivir
exist
prevent
treatment
influenza
limit
efficaci
due
rapid
evolut
viru
mutat
yearli
basi
sudden
unexpect
emerg
pandem
influenza
strain
effect
recent
annual
influenza
vaccin
date
mostli
base
ha
rare
na
surfac
glycoprotein
languish
success
influenza
season
particular
failur
vaccin
across
winter
season
overal
adjust
effect
confid
interv
memor
mismatch
year
mortal
rate
increas
atrisk
popul
problem
ensur
season
vaccin
correctli
match
upcom
circul
strain
highlight
need
rapid
develop
interseasonalunivers
vaccin
also
need
way
test
effici
rapidli
accur
lengthi
expens
mass
product
engag
take
mani
month
antivir
drug
exist
current
na
inhibitor
oseltamivir
commonli
use
activ
known
na
subtyp
influenza
one
would
therefor
assum
influenza
strain
may
decreas
effect
emerg
resist
influenza
strain
na
protein
chang
prevent
effici
oseltamivir
bind
thu
abil
inhibit
essenti
activ
viral
na
exampl
one
genet
mutat
known
substitut
histidin
tyrosin
na
posit
confer
evolutionari
advantag
viru
includ
influenza
influenza
season
influenza
viru
isol
us
state
oseltamivir
resist
substitut
isol
resist
zanamivir
although
anim
studi
demonstr
limit
transmiss
mutant
virus
thought
rise
oseltamivir
resist
may
due
commun
transmiss
rather
mutat
becom
fix
viral
genom
asystemat
systemat
review
metaanalysi
publish
data
onward
conclud
rsvassoci
child
death
occur
particularli
preterm
infant
infant
age
effect
matern
rsv
vaccin
monoclon
antibodi
could
substanti
effect
diseas
burden
age
group
rsvspecif
monoclon
antibodi
palivizumab
approv
prevent
seriou
lri
caus
rsv
suscept
infant
econom
benefit
uk
health
set
shown
due
high
cost
lack
benefit
seriou
outcom
singlecentr
cohort
studi
infant
show
differ
treatment
outcom
patient
receiv
palivizumab
compar
patient
receiv
standard
care
treatment
despit
lack
evid
clinic
benefit
postlicensur
data
support
use
palivizumab
reduc
rsvassoci
hospitalis
prematur
infant
week
children
chronic
lung
heart
diseas
importantli
palivizumab
resist
mutant
viru
rare
isol
clinic
specimen
rsv
treatment
ribavirin
limit
due
difficulti
aerosol
deliveri
cost
potenti
harm
healthcar
worker
despit
offlabel
treatment
immunocompromis
patient
reason
success
immunocompromis
therapi
concomit
immunoglobulin
palivizumab
mix
result
probabl
due
difficulti
know
initi
treatment
despit
call
acceler
develop
prevent
treatment
strategi
effect
rsv
vaccin
children
research
stall
decad
sinc
death
two
subject
clinic
studi
subject
infect
communityacquir
rsv
infect
receiv
us
nation
institut
health
nih
formalininactiv
alumprecipit
rsv
candid
vaccin
contrast
influenza
vaccin
date
shown
moder
effect
need
improv
rsv
vaccin
requir
substanti
research
current
licens
vaccin
rsv
advanc
candid
vaccin
recent
fail
show
efficaci
field
studi
effect
treatment
urgent
requir
rsv
even
amongst
healthcar
profession
consid
childhood
diseas
confound
obscur
understand
consequ
rsv
adult
rsv
poorli
understood
diseas
elderli
morbid
mortal
children
import
clearli
shown
rsv
compar
health
burden
influenza
elderli
exampl
recent
studi
conduct
adult
year
patient
admit
emerg
depart
suspect
ari
n
multiplex
pcr
use
diagnos
caus
respiratori
infect
eightyseven
patient
identifi
rsv
compar
group
influenza
utilis
base
allcaus
mortal
endpoint
adult
patient
less
like
diagnos
rsv
flu
vs
respect
also
older
often
diagnos
pneumonia
copd
hypoxemia
bacteri
coinfect
rsv
infect
elderli
significantli
associ
greater
risk
death
season
influenza
adjust
potenti
confound
comorbid
clinic
signific
viralbacteri
coinfect
long
controversi
topic
sever
bacteri
pneumonia
follow
influenza
infect
well
describ
associ
less
clear
among
infect
caus
virus
common
young
children
secondari
infect
due
virus
less
well
understood
review
other
although
assess
overal
contribut
bacteria
diseas
sever
complic
presenc
mani
confound
factor
clinic
studi
understand
role
viralbacteri
coinfect
defin
outcom
paediatr
ari
may
potenti
reveal
novel
treatment
prevent
strategi
improv
patient
outcom
recent
public
consid
role
bacteri
colonis
streptococcu
pneumonia
haemophilu
influenza
moraxella
catarrhali
symptomat
asymptomat
viral
upper
respiratori
infect
nasopharynx
children
uri
well
use
multiplex
pcr
viru
detect
upper
respiratori
tract
infect
uri
children
also
detect
nasopharynx
asymptomat
children
three
bacteria
level
higher
acut
uri
visit
compar
asymptomat
surveil
visit
children
note
howev
even
asymptomat
followup
visit
viru
present
bacteria
detect
higher
level
worth
note
presenc
confound
infect
mask
import
primari
aetiolog
taylor
et
al
report
incid
hbov
follow
identif
respiratori
tract
sampl
children
import
respiratori
pathogen
children
howev
role
viru
pathogen
signific
initi
unclear
coinfect
virus
bacteria
common
confound
moesker
et
al
studi
whether
hbov
alon
could
caus
acut
respiratori
infect
children
use
next
gener
sequenc
ng
abl
exclud
coinfect
amongst
admit
intens
care
unit
studi
hbov
viral
load
children
test
posit
respiratori
viru
rtpcr
hbov
rsv
detect
children
respect
fortynin
hbovposit
patient
rsvposit
patient
admit
intens
care
seven
hbovinfect
case
sever
ari
coinfect
importantli
children
anoth
detect
viru
determin
highli
sensit
ng
also
much
higher
hbov
load
patient
posit
hbov
ie
coinfect
although
small
studi
provid
strong
support
hbov
caus
seriou
ari
children
viral
bacteri
coinfect
histori
human
viral
challeng
model
sinc
sir
edward
jenner
perform
first
document
hvc
studi
smallpox
th
may
use
studi
appar
centuri
later
sir
christoph
andrew
return
us
observ
use
chimpanze
studi
influenza
fund
similar
work
uk
insuffici
therefor
sir
christoph
enrol
student
st
bartholomew
hospit
london
explain
next
best
thing
would
bart
student
cheaper
chimpanze
student
immedi
enrol
continu
studi
isol
way
chimpanze
usa
unfortun
investig
believ
symptom
observ
may
due
challeng
viru
respiratori
infect
acquir
commun
thu
confound
studi
year
later
uk
medic
research
council
mrc
termin
work
conclus
world
war
ii
withdraw
us
troop
uk
left
american
red
cross
harvard
hospit
field
unit
salisburi
plain
hospit
becam
common
cold
unit
ccu
led
dr
david
tyrel
volunt
inocul
instil
small
quantiti
viru
nose
ccu
hous
healthi
volunt
rel
isol
peopl
therebi
reduc
risk
contact
communityacquir
sourc
infect
pass
viru
member
public
unit
eventu
close
four
decad
research
attract
volunt
research
contribut
better
understand
respiratori
virus
viral
lifecycl
possibl
vaccin
well
first
licens
antiinfluenza
compound
amantadin
use
healthi
volunt
hvc
model
provid
still
offer
uniqu
opportun
describ
viral
lifecycl
investig
know
certainti
time
infect
nasal
viru
shed
measur
symptom
record
prospect
particip
select
low
preexist
immun
challeng
viru
ensur
statist
signific
infect
rate
small
number
volunt
thu
studi
maximis
safeti
efficaci
data
obtain
minimis
risk
studi
volunt
limit
research
fund
although
serum
igg
influenza
viru
tradit
measur
via
hai
assay
entri
criteria
volunt
studi
micro
neutralis
assay
use
rsv
hrv
work
suggest
screen
antibodi
na
influenza
surfac
protein
consid
tcell
respons
intern
protein
consid
closur
ccu
experiment
infect
studi
continu
usa
use
small
motel
hotel
replac
hut
salisburi
plain
studi
contribut
signific
develop
new
na
inhibitor
includ
inhal
drug
zanamivir
oral
avail
drug
oseltamivir
studi
howev
also
continu
uk
specif
univers
southampton
perform
import
work
atop
volunt
demonstr
sever
cold
experiment
challeng
rhinoviru
nonatop
control
experiment
atexa
influenza
viru
use
success
implic
develop
myocard
experiment
infect
subject
although
causal
link
never
demonstr
howev
incid
halt
work
usa
substanti
period
challeng
virus
manufactur
accord
good
manufactur
practic
gmp
standard
although
control
nasal
inocul
differ
natur
occur
infectionin
exposur
variabl
quantiti
viru
may
occur
variou
mucos
site
develop
hvc
model
use
challeng
studi
mimic
natur
diseas
far
possibl
describ
product
new
gmp
stock
viru
use
isol
experiment
infect
healthi
femal
volunt
provid
colleagu
univers
virginia
children
hospit
usa
importantli
clinic
sampl
provid
appropri
medic
histori
consent
donor
manufactur
new
stock
minim
passag
cell
line
reduc
risk
mutat
good
manufactur
practic
process
first
subject
stock
rigor
adventiti
agent
test
determin
viru
suitabl
human
use
conduct
initi
safeti
pathogen
clinic
studi
adult
volunt
dedic
clinic
quarantin
facil
london
group
start
hvc
studi
uk
sinc
conduct
multipl
studi
volunt
inocul
influenza
respiratori
syncyti
viru
rsv
human
rhinoviru
hrv
provid
numer
proof
concept
human
viral
challeng
model
shorten
drug
develop
pathway
ari
influenza
rsv
hrv
infect
similar
symptomatolog
differ
sever
predomin
upper
lower
system
symptom
describ
center
diseas
control
howev
easi
diagnos
differ
aetiolog
ari
better
diagnost
need
symptom
common
infect
manifest
gradient
gener
far
alway
influenza
infect
like
result
patient
feel
unwel
take
bed
fever
rsv
hrv
cov
common
cold
viru
infect
daili
life
usual
less
impact
varieti
anim
model
exist
research
respiratori
virus
influenza
rsv
hrv
singl
anim
offer
platform
respiratori
virus
infect
human
differ
anim
model
exist
viru
give
differ
often
conflict
result
addit
principl
replac
reduct
refin
develop
year
ago
provid
guidanc
ensur
human
anim
research
time
becom
nation
intern
legislationregul
polici
organis
fund
conduct
anim
research
includ
principl
part
condit
fund
share
symptomatolog
respiratori
virus
requir
singl
standard
research
platform
use
evalu
respiratori
diseas
pathogenesi
efficaci
candid
therapeut
use
dedic
purposebuilt
ensuit
bedroom
isol
facil
care
screen
volunt
safe
inocul
challeng
virus
intens
monitor
may
help
reduc
use
anim
provid
singl
consist
research
platform
standardis
evalu
endpoint
respiratori
viru
research
also
use
standardis
diari
card
across
studi
allow
comparison
symptom
viru
caus
efficaci
therapeut
test
includ
copi
diari
card
addit
file
difficult
evalu
efficaci
specif
antivir
therapeut
field
due
presenc
circul
commun
coinfect
differ
microbi
aetiolog
hvc
model
allow
opportun
studi
viru
isol
hvc
studi
field
studi
complementari
research
stratagem
necessari
develop
effect
ari
therapeut
contemporari
hvc
trial
fig
healthi
volunt
administ
investig
therapeut
either
prophylaxi
trial
treatment
trial
inocul
specif
challeng
strain
viru
virus
use
hvc
model
attenu
produc
symptom
consist
clinic
observ
ari
viru
propag
gmp
condit
minim
number
passag
isol
challeng
stock
mutat
occur
within
viru
rapidli
select
due
genet
bottleneck
consequ
viru
human
host
consid
wildtyp
similar
viru
recov
inocul
host
origin
refer
viru
strain
provid
assur
model
diseas
process
close
align
refer
viru
strain
alter
attenu
limit
licens
therapeut
option
respiratori
virus
highlight
signific
unmet
medic
need
model
hvc
allow
rapid
evalu
novel
therapeut
model
shorten
preclin
earli
clinic
develop
phase
provid
better
understand
host
pathogen
initi
interact
potenti
make
necessari
vaccin
medicin
rapidli
avail
tradit
develop
approach
otherwis
might
shorten
tradit
develop
pathway
earli
use
proof
concept
poc
studi
incorpor
hvc
model
fig
provid
essenti
evalu
endpoint
unlik
convent
phase
studi
rare
includ
assess
efficaci
almost
hvc
studi
includ
evalu
efficaci
endpoint
reduct
auc
viral
load
mainli
recov
upper
respiratori
tract
sampl
nasal
wash
nasopharyng
swab
volunt
selfreport
symptom
peak
symptom
score
total
symptom
score
amongst
other
small
number
subjectsoften
order
per
treatment
groupar
typic
includ
rapid
execut
short
durat
studi
result
safeti
pharmacokinet
pk
pharmacodynam
pd
data
control
condit
guid
decis
whether
progress
field
studi
provid
valuabl
set
data
immedi
even
part
convent
phase
safeti
studi
hvc
model
also
open
differ
develop
rout
alongsid
tradit
phase
allow
rapid
progress
statist
power
phase
studi
gener
efficaci
data
need
support
licens
still
provid
suitabl
safeti
data
fda
guidanc
develop
influenza
therapeut
state
challeng
trial
take
place
efficaci
phase
trial
guidanc
state
trial
provid
use
exposurerespons
safeti
inform
well
opportun
demonstr
pharmacolog
antivir
activ
human
control
condit
outsid
influenza
season
specif
data
challeng
trial
contribut
dose
select
phase
phase
trial
provid
opportun
explor
effect
differ
time
drug
initi
rel
viru
exposur
challeng
trial
refin
close
gap
experiment
infect
model
natur
infect
set
hvc
studi
durat
sever
week
shorter
fieldbas
phase
studi
wait
natur
outbreak
viru
durat
sever
monthsyear
studi
save
fig
human
viral
challeng
model
studi
typic
consist
input
volunt
select
criteria
isol
quarantin
exposur
gmp
viru
two
treatment
option
vaccinationprophylaxi
antivir
b
treatment
antivir
output
studi
summaris
right
viru
symptom
viru
shed
etc
x
number
day
viru
exposur
vaccin
may
occur
number
day
post
viru
exposur
volunt
may
follow
develop
time
transit
phase
fulli
optimis
importantli
unlik
tradit
phase
studi
hvc
studi
depend
natur
outbreak
infect
occur
random
exact
time
infect
may
appar
provid
evalu
endpoint
compar
pd
pk
data
along
addit
biomark
data
product
perform
human
must
howev
state
often
studi
enrol
otherwis
healthi
young
adult
impli
outcom
infect
placebo
group
may
seen
mild
moder
extent
safeti
volunt
remain
prioriti
investig
hrvhvc
model
potent
tool
studi
hrv
infect
diseas
also
investig
mechan
exacerb
patient
chronic
respiratori
diseas
conduct
efficaci
studi
new
therapi
human
challeng
studi
hrv
shown
produc
infect
serolog
suscept
subject
result
clinic
syndrom
compar
report
natur
cold
symptom
usual
appear
within
hour
peak
hour
inocul
viru
shed
follow
pattern
similar
symptom
recent
time
sever
hundr
inocul
adult
subject
report
establish
safe
effect
method
studi
hrvrelat
diseas
healthi
asthmat
subject
studi
provid
knowledg
base
develop
hrv
experiment
model
provid
control
use
tool
develop
new
therapi
diseas
area
associ
hrv
infect
new
treatment
asthma
copd
urgent
need
small
anim
model
asthma
poorli
predict
efficaci
drug
effect
anim
model
found
effect
later
stage
develop
human
model
close
follow
clinic
featur
human
asthma
copd
need
alreadi
describ
current
influenza
antivir
drug
shorten
diseas
reduc
sever
symptom
taken
earli
enough
infect
prophylact
use
decreas
risk
infect
util
debat
howev
two
main
class
current
effect
antiinfluenza
drug
na
inhibitor
zanamivir
oseltamivir
peramivir
inhibitor
although
drug
resist
make
class
unus
hvc
model
recent
use
extens
evalu
new
class
antivir
compound
influenza
includ
experiment
monoclon
antibodi
target
epitop
within
highli
conserv
expos
part
viral
surfac
fig
role
hvc
model
clinic
develop
pathway
short
durat
proof
concept
studi
incorpor
hvc
model
typic
includ
small
number
subject
result
safeti
particularli
efficaci
data
accur
guid
decis
whether
expos
larger
number
subject
promis
candid
therapeut
field
studi
convent
phase
safeti
data
alon
otherwis
might
protein
conserv
stalk
ha
small
molecul
antivir
drug
target
viral
polymeras
eg
favipiravir
hvc
model
allow
rapid
evalu
novel
therapeut
compound
may
difficult
evalu
field
due
natur
risk
group
eg
paediatr
specif
given
describ
histor
experi
rsv
vaccin
import
benefit
first
demonstr
healthi
popul
past
unlik
influenza
hrv
hvc
model
routin
use
rsv
recent
howev
sever
antivir
therapeut
reach
advanc
stage
develop
use
model
time
wish
restart
hvcrsv
studi
univers
london
two
signific
challeng
stall
antivir
develop
rsv
present
consider
research
need
associ
devincenzo
lab
univers
tenesse
biotech
compani
alnylam
set
design
possibl
first
hvcrsv
studi
alnylam
pioneer
use
rna
interfer
rnai
natur
mechan
regul
protein
express
mediat
small
interf
rna
sirna
work
group
manufactur
rsv
type
viru
gmp
standard
titrat
human
volunt
divid
five
group
intranas
inocul
increas
titr
log
plaqueform
unitsperson
challeng
viru
intranas
overal
new
model
volunt
consist
shed
viru
infect
rate
viral
load
diseas
sever
safeti
similar
cohort
unrel
quantiti
rsv
receiv
symptom
began
soon
initi
viral
detect
peak
sever
near
viral
load
peak
subsid
viral
load
slowli
declin
conclud
regardless
titr
administ
infect
establish
viral
load
drove
ill
saw
advers
event
link
viru
use
new
model
conduct
hvc
clinic
studi
demonstr
first
time
rnai
signific
antivir
activ
human
rsv
infect
establish
firstev
proof
concept
rnai
therapeut
human
adult
editori
american
journal
respiratori
critic
care
medicin
describ
util
hvcrsv
model
say
model
permit
rel
quick
effici
studi
new
therapeut
human
assist
make
critic
decis
whether
advanc
product
costli
human
trial
popul
highest
risk
diseas
children
elderli
immunocompromis
patient
constitut
major
welcom
advanc
field
rsv
notabl
two
compound
distinct
mode
action
recent
evalu
use
hvc
model
firstinclass
nucleosid
analogu
efficaci
first
demonstr
hvc
model
current
evalu
hospitalis
infant
hvc
trial
randomis
doubleblind
design
studi
healthi
adult
inocul
rsv
memphi
total
particip
receiv
placebo
five
day
confirm
rsv
infect
pcr
test
twice
daili
post
inocul
primari
endpoint
area
curv
auc
viral
load
post
infect
rapid
rsv
clearanc
greater
reduct
viral
load
accompani
improv
sever
clinic
diseas
demonstr
group
treat
compar
placebo
group
intens
sampl
allow
potenti
mutat
associ
resist
rapidli
identifi
resist
mutat
observ
rsventri
inhibitor
second
molecul
firstin
class
also
evalu
among
subject
receiv
activ
treatment
lower
viral
load
lower
total
mucu
weight
lower
auc
symptom
score
highli
signific
compar
placebo
base
challeng
studi
data
therapeut
also
progress
potenti
pivot
field
studi
essenti
element
design
studi
time
first
administr
therapeut
postexperiment
viru
inocul
time
depend
detect
viru
nasal
wash
sampl
post
inocul
challeng
viru
rapid
pcr
assay
rather
arbitrari
time
point
subsequ
therapeut
administ
everi
hour
care
dose
time
clinic
relev
point
detect
contribut
posit
outcom
studi
also
believ
use
trigger
dose
model
better
mimick
would
happen
clinic
set
symptom
known
appear
soon
onset
viru
shed
hvc
model
limit
novel
antivir
compound
also
import
evalu
novel
vaccin
influenza
vaccin
perform
recent
year
rais
question
appropri
correl
protect
unlik
field
studi
hvc
studi
use
tool
assess
correl
protect
vital
vaccin
develop
specif
import
humor
cellular
respons
highlight
along
preexist
tcell
immun
respiratori
virus
recent
public
describ
use
hvc
model
demonstr
efficaci
novel
intranas
proteosomeadjuv
trival
inactiv
influenza
vaccin
ptiv
two
separ
studi
select
subject
viru
dose
via
nasal
spray
one
three
regimen
ptiv
placebo
togeth
studi
evalu
one
two
dose
either
twice
day
apart
x
x
x
subject
challeng
viru
immun
respons
vaccin
antigen
measur
haemagglutin
inhibit
hai
assay
nasal
wash
secretori
iga
siga
antibodi
vaccin
efficaci
observ
rang
compar
tradit
vaccin
studi
also
demonstr
protect
ill
associ
evid
influenza
infect
significantli
correl
prechalleng
hai
serum
igg
titr
p
mucos
iga
individu
hai
p
siga
p
togeth
hai
siga
level
invers
relat
rate
ill
studi
demonstr
efficaci
novel
intranas
vaccin
answer
import
question
concern
true
correl
protect
influenza
infect
help
drive
futur
vaccin
design
well
achiev
primari
aim
reveal
valuabl
insight
correl
protect
hope
aid
futur
vaccin
design
interseason
univers
influenza
vaccin
desper
need
save
mani
live
whether
unexpect
year
recommend
composit
match
pandem
occur
signific
pandem
make
clear
million
peopl
die
univers
vaccin
one
prepar
unexpect
viru
occur
due
reassort
viral
gene
differ
host
speci
hvc
model
possibl
way
initi
test
univers
vaccin
univers
candid
could
gener
immun
respons
highli
conserv
viru
ion
channel
protein
although
vaccin
shown
effect
regard
monoclon
antibodi
alon
hvc
model
show
efficaci
altern
vaccin
may
target
conserv
stalk
ha
protein
elicit
tcell
respons
intern
protein
possibl
explor
effici
use
hvc
model
although
hvc
studi
provid
poc
research
shown
employ
regulatori
design
standard
typic
later
phase
efficaci
studi
develop
molecular
technolog
possibl
refin
statist
analysi
stratifi
subject
base
immun
profil
instanc
possibl
assess
whether
subject
carri
known
respiratori
pathogen
bacteria
virus
etc
possibl
impact
set
result
volunt
subject
often
consent
analysi
sampl
allow
valuabl
biobank
sampl
built
test
move
forward
sampl
allow
use
hvc
model
understand
happen
viru
infect
person
worth
note
hvc
model
limit
poc
work
potenti
therapeut
agent
also
extens
use
research
purpos
upon
improv
treatment
respiratori
virus
built
recent
year
use
demonstr
gene
switch
signatur
could
form
part
diagnost
would
reveal
infect
individu
becom
symptomat
earli
stage
infect
could
vital
import
event
pandem
also
hvc
model
use
allow
comparison
rel
diseas
dynam
differ
respiratori
virus
provid
better
understand
interact
viru
human
host
hvc
model
increas
understand
viral
life
cycl
diseas
pathogenesi
tightli
control
set
use
small
number
volunt
volunt
isol
wider
commun
ensur
diseas
consider
one
interest
applic
viru
use
challeng
volunt
hvc
model
viru
individu
might
becom
expos
real
world
signific
whether
challeng
trial
feasibl
depend
avail
adequ
safetytest
challeng
viru
strain
know
provid
hvc
model
provid
certain
knowledg
charact
viru
exact
time
point
infect
measur
nasal
viru
shed
prospect
record
symptom
preselect
particip
viral
challeng
serosuit
ensur
statist
signific
rate
infect
achiev
minim
number
volunt
thu
optimis
riskbenefit
ratio
support
determin
therapeut
efficaci
crucial
hvc
studi
design
time
administr
first
dose
product
investig
determin
optim
effect
challeng
studi
later
stage
clinic
studi
final
clinic
use
hvc
model
import
tool
drug
develop
particular
regard
acut
respiratori
infect
acceler
develop
therapeut
address
multipl
unmet
medic
need
help
understand
relationship
viru
human
host
offer
potenti
develop
earlystag
diagnost
contribut
toward
identifi
new
area
therapeut
intervent
possibl
arguabl
importantli
ensur
scarc
medic
resourc
direct
toward
later
stage
clinic
develop
evidencebas
manner
promis
therapeut
opportun
prioritis
care
target
studi
design
process
crucial
step
toward
success
outcom
challeng
trial
almost
paramet
either
control
least
known
either
preor
posthoc
furthermor
result
trial
use
make
commerci
decis
lead
major
public
expand
collect
understand
scientif
commun
sampl
experi
immens
valu
research
understand
host
interact
mechan
develop
valid
therapeut
utilis
consist
collect
histor
data
hvc
studi
inform
accur
design
power
subsequ
studi
hvc
studi
success
provid
proof
concept
dna
vaccin
tcell
vaccin
intranas
vaccin
monoclon
antibodi
small
molecul
rang
import
respiratori
virus
also
encourag
see
hvc
model
expand
patient
popul
elderli
asthmat
condit
chronic
obstruct
pulmonari
diseas
expand
archiv
data
preced
studi
invalu
asset
assist
select
volunt
decid
appropri
endpoint
refin
futur
field
studi
design
allow
safer
statist
sound
rapidli
deliv
research
draft
initi
version
manuscript
author
rlw
hvivo
respons
overal
manag
work
verifi
accuraci
data
present
nonauthor
contributor
includ
ben
murdoch
hvivo
provid
figur
hvivo
would
like
thank
volunt
without
whose
altruism
human
viral
challeng
studi
conduct
hvivo
mani
year
would
possibl
work
includ
profession
medic
write
servic
prepar
manuscript
wholli
fund
hvivo
servic
limit
employ
author
author
rlw
conceiv
strategi
paper
author
rlw
profession
medic
writer
samina
hamilton
draft
articl
see
acknowledg
author
rlw
ag
critic
review
complet
articl
import
intellectu
content
author
rlw
ag
full
author
choic
journal
approv
final
articl
author
rlw
guarantor
paper
take
overal
respons
public
author
contribut
write
review
manuscript
ethic
approv
consent
particip
clinic
studi
describ
receiv
appropri
ethic
committe
approv
includ
inform
consent
volunt
author
declar
employe
hvivo
provid
provid
ethic
profession
clinic
research
servic
academ
biotechnolog
pharmaceut
client
patent
patent
applic
us
ep
applic
progress
regard
specif
utilis
hvc
model
alter
author
adher
intern
societi
medic
public
profession
ismpp
good
public
practic
commun
companysponsor
medic
research
